Merck Serono taps Threshold for Ph III cancer drug
This article was originally published in Scrip
Merck KGaA has paid €19 million ($25 million) up front to access a small-molecule drug targeting tumour hypoxia from Threshold Pharmaceuticals of South San Francisco, California. The compound, TH-302, is in Phase III for soft tissue sarcoma and in Phase II for advanced pancreatic cancer, with results expected for the latter in the next few days. Threshold noted that total milestone payments could reach $525 million, with $280 million related to regulatory and development milestones and $245 million from sales-based milestones.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.